ADPKD
Advertisement
RGLS8429 increases urinary PC1 and PC2 proteins, which may help reduce height-adjusted total kidney volume in ADPKD.
Could pravastatin slow the rate of increase in height-adjusted total kidney volume in adults with ADPKD?
Researchers assessed the safety and efficacy of bardoxolone methyl (BARD) in patients with ADPKD.
Recent research reveals tolvaptan’s role in reducing hemodialysis initiation risk in ADPKD,
A study examined physician confidence and barriers to prescription of tolvaptan for the management of ADPKD.
A study investigated whether treatment with difelikefalin and tolvaptan can protect against worsening of late-stage PKD.
ESSENTIAL assessed the safety and effectiveness of tolvaptan among patients in Korea with ADPKD and CKD stages 1 to 3.
Tolvaptan increased serum sodium without causing sodium overcorrection in syndrome of inappropriate antidiuresis.
Researchers compared factors associated with intracranial aneurysm in patients with ADPKD.
The FDA granted orphan drug designation to AP303 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Nephrologist Ronald Perrone, MD, has joined the clinical advisory board of XORTX Therapeutics, Inc.
The FDA approved a clinical trial of VX-407 to treat autosomal dominant polycystic kidney disease.
Researchers examined the association between good nutritional status and preservation of kidney function in ADPKD.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.